Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 2
2005 2
2006 9
2007 6
2008 5
2009 3
2010 5
2011 6
2012 4
2013 3
2014 1
2015 1
2016 1
2017 1
2018 1
2019 1
2021 5
2022 5
2023 5
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

66 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
Trial of Lixisenatide in Early Parkinson's Disease.
Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group. Meissner WG, et al. Among authors: benatru i. N Engl J Med. 2024 Apr 4;390(13):1176-1185. doi: 10.1056/NEJMoa2312323. N Engl J Med. 2024. PMID: 38598572 Clinical Trial.
Trial of Botulinum Toxin for Isolated or Essential Head Tremor.
Marques A, Pereira B, Simonetta-Moreau M, Castelnovo G, De Verdal M, Fluchère F, Laurencin C, Degos B, Tir M, Kreisler A, Blanchet-Fourcade G, Guehl D, Colin O, Poujois A, Sangla S, Tatu L, Derost P, Gayraud D, Tranchant C, Amarantini D, Devos D, Rascol O, Corvol JC, Durif F, Rieu I; Btx-HT Study Group. Marques A, et al. N Engl J Med. 2023 Nov 9;389(19):1753-1765. doi: 10.1056/NEJMoa2304192. N Engl J Med. 2023. PMID: 37937777 Clinical Trial.
Overview on wearable sensors for the management of Parkinson's disease.
Moreau C, Rouaud T, Grabli D, Benatru I, Remy P, Marques AR, Drapier S, Mariani LL, Roze E, Devos D, Dupont G, Bereau M, Fabbri M. Moreau C, et al. Among authors: benatru i. NPJ Parkinsons Dis. 2023 Nov 2;9(1):153. doi: 10.1038/s41531-023-00585-y. NPJ Parkinsons Dis. 2023. PMID: 37919332 Free PMC article. Review.
[Post-stroke depression, another handicap].
Pinoit JM, Bejot Y, Rouaud O, Benatru I, Osseby GV, Bonin B, Gisselmann A, Giroud M. Pinoit JM, et al. Among authors: benatru i. Presse Med. 2006 Dec;35(12 Pt 1):1789-93. doi: 10.1016/s0755-4982(06)74903-x. Presse Med. 2006. PMID: 17159729 Free article. Review. French.
Postural disorders in Parkinson's disease.
Benatru I, Vaugoyeau M, Azulay JP. Benatru I, et al. Neurophysiol Clin. 2008 Dec;38(6):459-65. doi: 10.1016/j.neucli.2008.07.006. Epub 2008 Aug 21. Neurophysiol Clin. 2008. PMID: 19026965 Review.
A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
Damier P, Degos B, Castelonovo G, Anheim M, Benatru I, Carrière N, Colin O, Defebvre L, Deverdal M, Eusebio A, Ferrier V, Giordana C, Houeto JL, Le Dily S, Mongin M, Thiriez C, Tranchant C, Ravel D, Corvol JC, Rascol O, Ben Ari Y. Damier P, et al. Among authors: benatru i. Mov Disord. 2024 Mar;39(3):618-622. doi: 10.1002/mds.29726. Epub 2024 Jan 30. Mov Disord. 2024. PMID: 38291616 Clinical Trial.
Adrafinil-induced orofacial dyskinesia.
Thobois S, Xie J, Mollion H, Benatru I, Broussolle E. Thobois S, et al. Among authors: benatru i. Mov Disord. 2004 Aug;19(8):965-6. doi: 10.1002/mds.20154. Mov Disord. 2004. PMID: 15300665
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.
Pagano G, Boess FG, Taylor KI, Ricci B, Mollenhauer B, Poewe W, Boulay A, Anzures-Cabrera J, Vogt A, Marchesi M, Post A, Nikolcheva T, Kinney GG, Zago WM, Ness DK, Svoboda H, Britschgi M, Ostrowitzki S, Simuni T, Marek K, Koller M, Sevigny J, Doody R, Fontoura P, Umbricht D, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. Front Neurol. 2021 Oct 1;12:705407. doi: 10.3389/fneur.2021.705407. eCollection 2021. Front Neurol. 2021. PMID: 34659081 Free PMC article.
66 results